Biomea Fusion, Inc. (BMEA) |
|
11.11 0.51 (4.81%)
|
08-19 02:04 |
|
Open: |
10.6 |
Pre. Close: |
10.6 |
|
High:
|
11.36 |
Low:
|
10.5504 |
|
Volume:
|
123,826 |
Market Cap:
|
325(M) |
|
|
|
|
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
13.82 - 13.89 |
13.89 - 13.94 |
|
Low:
|
9.69 - 9.74 |
9.74 - 9.79 |
|
Close:
|
10.51 - 10.61 |
10.61 - 10.68 |
|
Technical analysis |
as of: 2022-08-18 3:51:13 PM |
|
Overall:
|
 |
| Stoxline posted a STRONG SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 14.61 One year: 16.56 |
| Support: |
Support1: 9.81 Support2: 8.16 |
| Resistance: |
Resistance1: 12.51 Resistance2: 14.18 |
| Pivot: |
11.48  |
| Moving Average: |
MA(5): 11.91 MA(20): 11.4
MA(100): 7.82  MA(250): 8.62 |
| MACD: |
MACD(12,26): 0.2 Signal(9): 0.3 |
| Stochastic oscillator: |
%K(14,3): 44.6 %D(3): 62 |
| RSI: |
RSI(14): 48.9 |
| 52-week: |
High: 14.85 Low: 2.83 |
| Average Vol(K): |
3-Month: 217 (K) 10-Days: 230 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BMEA ] has closed above bottom band by 39.3%. Bollinger Bands are 11.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 18 Aug 2022
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday By Benzinga - Investing.com UK
Wed, 17 Aug 2022
Healthcare Stocks Moving Wednesday: BWV, EAR, SAVA, BIVI, PAVM, UBX, BMEA, OMIC - InvestorsObserver
Sun, 14 Aug 2022
Short Interest in Biomea Fusion, Inc. (NASDAQ:BMEA) Drops By 17.2% - MarketBeat
Fri, 12 Aug 2022
We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth - Nasdaq
Sat, 06 Aug 2022
Biomea Fusion, Inc. (NASDAQ:BMEA) Expected to Earn Q3 2022 Earnings of ($0.64) Per Share - Defense World
Fri, 29 Jul 2022
Short Interest in Biomea Fusion, Inc. (NASDAQ:BMEA) Decreases By 78.2% - Defense World
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
29 (M) |
| Shares Float |
20 (M) |
|
% Held by Insiders
|
34.7 (%) |
|
% Held by Institutions
|
63.8 (%) |
|
Shares Short
|
545 (K) |
|
Shares Short P.Month
|
2,860 (K) |
Stock Financials |
|
EPS
|
-1.86 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
5.13 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-20.7 |
|
Return on Equity (ttm)
|
-34.6 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.08 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-50 (M) |
|
Levered Free Cash Flow
|
-30 (M) |
Stock Valuations |
|
PE Ratio
|
-6.03 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.16 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-6.5 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
